title: Antiviral agents for herpes simplex virus.
abstract: This review starts with a brief description of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), the clinical diseases they cause, and the continuing clinical need for antiviral chemotherapy. A historical overview describes the progress from the early, rather toxic antivirals to acyclovir (ACV) which led the way for its prodrug, valacyclovir, to penciclovir and its prodrug, famciclovir (FCV). These compounds have been the mainstay of HSV therapy for two decades and have established a remarkable safety record. This review focuses on these compounds, the preclinical studies which reveal potentially important differences, the clinical trials, and the clinical experience through two decades. Some possible areas for further investigation are suggested. The focus shifts to new approaches and novel compounds, in particular, the combination of ACV with hydrocortisone, known as ME609 or zovirax duo, an HSV helicase-primase inhibitor, pritelivir (AIC316), and CMX001, the cidofovir prodrug for treating resistant HSV infection in immunocompromised patients. Letermovir has established that the human cytomegalovirus terminase enzyme is a valid target and that similar compounds could be sought for HSV. We discuss the difficulties facing the progression of new compounds. In our concluding remarks, we summarize the present situation including a discussion on the reclassification of FCV from prescription-only to pharmacist-controlled for herpes labialis in New Zealand in 2010; should this be repeated more widely? We conclude that HSV research is emerging from a quiescent phase.
authors.affiliation: Vere Hodge Antivirals Ltd., Surrey, United Kingdom.
authors.forename: R Anthony
authors.initials: RA
authors.lastname: Vere Hodge
authors.forename: Hugh J
authors.initials: HJ
authors.lastname: Field
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D055808:Drug Discovery; D024882:Drug Resistance, Viral; D006147:Guanine; D006561:Herpes Simplex / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D018139:Simplexvirus / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; C053539:penciclovir; D006147:Guanine; D000212:Acyclovir
keywords: Antiviral chemotherapy; CMX001; Famciclovir; HSV; Pritelivir; Valacyclovir